Sofosbuvir/ribavirin safely, effectively treated patients with HIV, HCV

A majority of patients with HIV and hepatitis C virus achieved sustained virologic response when treated with sofosbuvir plus ribavirin, according to research presented at the International AIDS Conference in Melbourne, Australia.

Investigators conducted the PHOTON-2 clinical trial with 274 patients (81% men) coinfected with HIV and hepatitis C virus (HCV), including genotypes 1, 2, 3 and 4. Ninety-seven percent of patients were receiving antiretroviral therapy (ART).

Treatment-naive patients with HCV genotype 1, 3 or 4 and treatment-experienced patients with genotype 2 or 3 received 400 mg sofosbuvir daily and 1,000 mg to 1,200 mg weight-based ribavirin daily for 24 weeks. Treatment-naive patients with HCV genotype 2 received therapy for 12 weeks.

Eighty-four percent of treatment-naive HCV patients with genotype 1 (n=112), 90% with genotype 2 (n=90), 91% with genotype 3 (n=57) and 84% with genotype 4 (n=31) achieved sustained virologic response (SVR) at 12 weeks. Treatment-experienced HCV patients with genotype 2 (n=6) achieved SVR at 12 weeks (83%), as did 86% of genotype 3 patients (n=49). Two percent of all patients discontinued treatment because of a serious adverse event (AE); 15 patients experienced a grade 3 or 4 AE. Six patients were lost to follow-up and 31 relapsed.

“HCV genotype 1-4 treatment-naive and experienced HIV coinfected patients achieved high rates of SVR12 with 12 or 24 weeks of an interferon-free, oral regimen of sofosbuvir plus ribavirin,” the researchers wrote. “Treatment was well tolerated and safely co-administered with multiple ART regimens.”

For more information:

Molina J-M. #MOAB0105LB. Presented at: 20^th International AIDS Conference; July 20-25, 2014; Melbourne, Australia.

Disclosure: Relevant financial disclosures were not provided by researchers.